GATA2 and myelodysplastic syndrome: Although the analysis presented here is limited to patients with MDS, the lack of evidence of increased transplant-related toxicity inherent to the GATA2 germline mutation indicates that in young individuals with GATA2 deficiency the indication for HSCT can be based on the expected clinical course.